A comparative study of iron isomaltoside versus iron sucrose in treating anemia in postpartum

• Author Details:   
• Prajakta Bajarang Bhosle ^*
• Shailaja R Bidri
• Rajasri G Yaliwal

---

Background: The most frequent hematological disorder identified during pregnancy is anemia. The World Health Organization defines anemia during pregnancy as having a hemocrit of less than 33% and a hemoglobin content of less than 11 grams per milliliter. This study aimed to examine the safety, effectiveness, of intravenous iron isomaltoside versus intravenous Iron sucrose in the treatment of postpartum anemia.

Materials and Methods: This Randomised parallel group trial study will be done in the Department of Obstretrics and Gynaecology Shri B. M. Patil Medical College Hospital and Research Centre. All postpartum women between day 1 and day 10 of normal delivery or cesarean section with moderate anaemia (Hb 7-11 gm/dl) admitted in labor room and wards and agreeing to give written and informed consent will be included in the study.

Then subjects will be randomized in to two groups in 1:1, 108 subjects in each group Group 1: One gram of intravenous iron isomaltoside was administered in a single dosage.  Group 2: 200 mg, 200 mg, and 200 mg of iron sucrose were given intravenously for three day totaling 600 mg.

Then the CBC and serum ferritin levels will be checked on the recruitment day followed by 21st day after therapy.

Result: The Hb increase experienced by women in the iron isomaltoside group was 1.4 gm more than that of the iron sucrose group, and this difference was statistically significant (P value <0>

Conclusion: Iron isomaltoside is an efficient alternative to Iron Sucrose in treating postpartum anemia. It has an added advantage of single dose regime and lower incidence of side effects.

Keywords: Iron isomaltoside, Iron sucrose, Postpartum anemia, Anemia, Anemia in puerperium.